<DOC>
	<DOCNO>NCT02750761</DOCNO>
	<brief_summary>This study ass pharmacokinetics ( PK ) tedizolid phosphate active metabolite , tedizolid , safety tedizolid phosphate follow administration single IV ( Part A ) oral suspension ( Part B ) administration hospitalize participant age 6 &lt; 12 year ( Groups 1 3 , respectively ) , 2 &lt; 6 year ( Groups 2 4 , respectively ) .</brief_summary>
	<brief_title>A Study Oral Intravenous ( IV ) Tedizolid Phosphate Hospitalized Participants , Ages 2 &lt; 12 Years , With Confirmed Suspected Bacterial Infection ( MK-1986-013 )</brief_title>
	<detailed_description>Part A ( IV ) : - Group 1 ( Cohort 1 Cohort 2 ) ( 6 &lt; 12 year ) - Group 2 ( Cohort 1 Cohort 2 ) ( 2 &lt; 6 year ) Part B ( Oral Suspension ) : - Group 3 ( 6 &lt; 12 year ) - Group 4 ( 2 &lt; 6 year ) In Cohort 1 Group 1 ( IV ) Group 3 ( oral suspension ) , participant receive single administration tedizolid phosphate 5 mg/kg total body weight . After participant Cohort 1 Group 1 receive study drug , preliminary analysis safety PK data perform result use confirm 5 mg/kg appropriate dose Cohort 2 Group 1 young participant , Cohort 1 Group 2 , subsequently , dose Cohort 2 Group 2 . Similarly , Group 4 dose confirm data review Group 3 result . If preliminary safety PK analysis suggest safety signal follow clinical review adverse event ( AEs ) indicate low likelihood achieving exposure within 2-fold exposure adult , dose adjust remain participant .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Gram-Positive Bacterial Infections</mesh_term>
	<mesh_term>Torezolid phosphate</mesh_term>
	<mesh_term>Torezolid</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Receiving prophylaxis confirm suspected infection Grampositive bacteria receive concurrent antibiotic treatment Grampositive antibacterial activity ; Weight &gt; 5th percentile &lt; 95th percentile base age ; Stable condition determine medical history , physical examination , minimally 5lead ECG , vital sign , clinical laboratory evaluation ; Females must premenarchal , abstinent , practice effective method birth control ; History seizure , febrile seizure , clinical significant cardiac arrhythmia , cystic fibrosis , moderate severe renal impairment , physical condition could interfere study result ; Recent ( 3 month ) history current infection viral hepatitis significant hepatic disease ; History drug allergy hypersensitivity oxazolidinones ; Pregnant breast feeding ; Significant blood loss within 60 day prior study start ; Any acute chronic condition would limit participant 's ability complete and/or participate clinical study . Treatment investigational medicinal product within 30 day infusion/dose study drug . Oral administration methotrexate , topotecan , irinotecan rosuvastatin , administration oral study drug . Administration followup period allow , administration treatment IV study drug .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>